Mid-Atlantic Division
CHTN_BRCaProg2 - Breast Cancer Progression
TMA Map
Code Key
Tissue List
| TMA code | Diagnosis | Age | Race | pT stage* | pN stage* | Estrogen Receptor† | Progesterone Receptor† | Her2 Amplification†† | Other samples from same subject |
|---|---|---|---|---|---|---|---|---|---|
| NB-NC-1 | Non-neoplastic breast from patients without breast carcinoma | 19 | B | N/A | N/A | N/A | N/A | N/A | |
| NB-NC-2 | Non-neoplastic breast from patients without breast carcinoma | 24 | B | N/A | N/A | N/A | N/A | N/A | |
| NB-NC-3 | Non-neoplastic breast from patients without breast carcinoma | 25 | W | N/A | N/A | N/A | N/A | N/A | |
| NB-NC-4 | Non-neoplastic breast from patients without breast carcinoma | 26 | B | N/A | N/A | N/A | N/A | N/A | |
| NB-NC-5 | Non-neoplastic breast from patients without breast carcinoma | 43 | W | N/A | N/A | N/A | N/A | N/A | |
| NB-NC-6 | Non-neoplastic breast from patients without breast carcinoma | 38 | B | N/A | N/A | N/A | N/A | N/A | |
| NB-NC-7 | Non-neoplastic breast from patients without breast carcinoma | 23 | B | N/A | N/A | N/A | N/A | N/A | |
| NB-C-1 | Non-neoplastic from breast carcinoma patients | 68 | W | pT1a | snpN0 | positive | positive | negative | |
| NB-C-2 | Non-neoplastic from breast carcinoma patients | 60 | W | mpT1c | snpN0 | positive | positive | negative | |
| NB-C-3 | Non-neoplastic from breast carcinoma patients | 67 | W | pT2 | pN0 | positive | positive | negative | ICL-2 |
| NB-C-4 | Non-neoplastic from breast carcinoma patients | 59 | W | pT2 | pN0 | positive | positive | positive | IDC-H-3 |
| NB-C-5 | Non-neoplastic from breast carcinoma patients | 44 | pT1c | pN0 | positive | negative | negative | ||
| NB-C-6 | Non-neoplastic from breast carcinoma patients | 39 | W | pTis(DCIS) | positive | ||||
| NB-C-7 | Non-neoplastic from breast carcinoma patients | 47 | W | pT1c | snpN0 | positive | positive | negative | IDC-L-5 |
| DCIS-L-1 | Ductal carcinoma in situ, low grade | 60 | B | pTis(DCIS) | snpN0 | positive | |||
| DCIS-L-2 | Ductal carcinoma in situ, low grade | 64 | B | pTis(DCIS) | positive | ||||
| DCIS-L-3 | Ductal carcinoma in situ, low grade | 43 | W | pT1b | pN0 | positive | positive | negative | |
| DCIS-L-4 | Ductal carcinoma in situ, low grade | 43 | W | pTis(DCIS) | snpN0 | positive | |||
| DCIS-L-5 | Ductal carcinoma in situ, low grade | 51 | W | pT1c | snpN0 | positive | positive | negative | |
| DCIS-L-6 | Ductal carcinoma in situ, low grade | 54 | pTis(DCIS) | pNx | positive | ||||
| DCIS-L-7 | Ductal carcinoma in situ, low grade | 58 | W | pTis(DCIS) | snpN0 | positive | positive | ||
| DCIS-H-1 | Ductal carcinoma in situ, high grade | 48 | B | pTis(DCIS) | positive | ||||
| DCIS-H-2 | Ductal carcinoma in situ, high grade | 50 | W | pTis(DCIS) | positive | ||||
| DCIS-H-3 | Ductal carcinoma in situ, high grade | 73 | W | pTis(DCIS) | snpN0 | positive | |||
| DCIS-H-4 | Ductal carcinoma in situ, high grade | 82 | B | pT2 | snpN0 | negative | negative | negative | |
| DCIS-H-5 | Ductal carcinoma in situ, high grade | 42 | W | pT1c | pN2a | positive | positive | negative | |
| DCIS-H-6 | Ductal carcinoma in situ, high grade | 56 | W | ypTis(DCIS) | ypN0 | negative | positive | positive | |
| DCIS-H-7 | Ductal carcinoma in situ, high grade | 37 | B | pTis(DCIS) | pN1a | positive | positive | negative | |
| IDC-L-1 | Invasive ductal carcinoma, grade 1 or 2 | 57 | B | pT2 | pN0 | positive | positive | positive | |
| IDC-L-2 | Invasive ductal carcinoma, grade 1 or 2 | 48 | W | ypT1c | pN2a | positive | negative | negative | LMN-6 |
| IDC-L-3 | Invasive ductal carcinoma, grade 1 or 2 | 61 | W | pT1c | pN0 | positive | positive | negative | |
| IDC-L-4 | Invasive ductal carcinoma, grade 1 or 2 | 31 | W | pT2 | snpN0 | positive | positive | negative | |
| IDC-L-5 | Invasive ductal carcinoma, grade 1 or 2 | 47 | B | pT1c | snpN0 | positive | positive | negative | |
| IDC-L-6 | Invasive ductal carcinoma, grade 1 or 2 | 48 | W | pT2 | pN2a | positive | positive | negative | NB-C-7 |
| IDC-L-7 | Invasive ductal carcinoma, grade 1 or 2 | 70 | W | pT2 | pN3a | positive | positive | negative | |
| IDC-H-1 | Invasive ductal carcinoma, grade 3 | 58 | B | ypT2 | ypN1a | negative | negative | negative | |
| IDC-H-2 | Invasive ductal carcinoma, grade 3 | 58 | O | ypT2 | ypN2a | positive | positive | negative | LNM-1 |
| IDC-H-3 | Invasive ductal carcinoma, grade 3 | 59 | W | pT2 | pN0 | positive | positive | positive | NB-C-4 |
| IDC-H-4 | Invasive ductal carcinoma, grade 3 | 77 | W | pT3 | pN1a | positive | positive | negative | |
| IDC-H-5 | Invasive ductal carcinoma, grade 3 | 79 | W | ypT4b | ypN1a | positive | positive | positive | LNM-7 |
| IDC-H-6 | Invasive ductal carcinoma, grade 3 | 64 | W | pT1b | snpN0 | negative | negative | negative | |
| IDC-H-7 | Invasive ductal carcinoma, grade 3 | 46 | W | pT2 | pN0 | negative | negative | positive | |
| ILC-1 | Invasive lobular carcinoma | 49 | W | pT1c | pN0 | positive | positive | negative | |
| ILC-2 | Invasive lobular carcinoma | 67 | W | pT2 | pN0 | positive | positive | negative | NB-C-3 |
| ILC-3 | Invasive lobular carcinoma | 65 | W | pT2 | pN0 | positive | positive | negative | |
| ILC-4 | Invasive lobular carcinoma | 64 | W | pT1c | pN1a | positive | positive | negative | |
| ILC-5 | Invasive lobular carcinoma | 59 | B | ypT2 | ysnpN0 | positive | positive | negative | |
| ILC-6 | Invasive lobular carcinoma | 76 | W | pT2 | pN3a | positive | negative | negative | |
| ILC-7 | Invasive lobular carcinoma | 75 | W | pT1c | pN0 | positive | positive | negative | |
| LNM-1 | Breast carcinoma metastatic to regional lymph nodes | 58 | O | ypT2 | ypN2a | positive | positive | negative | IDC-H-2 |
| LNM-2 | Breast carcinoma metastatic to regional lymph nodes | 85 | W | pT4b | pN1a | positive | positive | negative | |
| LNM-3 | Breast carcinoma metastatic to regional lymph nodes | 39 | B | pT2 | pN2a | positive | positive | negative | |
| LNM-4 | Breast carcinoma metastatic to regional lymph nodes | 54 | B | pT1a | pN1a | positive | positive | negative | |
| LNM-5 | Breast carcinoma metastatic to regional lymph nodes | 62 | W | pT1c | pN3a | negative | negative | negative | |
| LNM-6 | Breast carcinoma metastatic to regional lymph nodes | 48 | W | pT1c | pN2a | positive | negative | negative | IDC-L-2 |
| LNM-7 | Breast carcinoma metastatic to regional lymph nodes | 79 | W | ypT4b | ypN1a | positive | positive | positive | IDC-H-5 |
| Race: W = white, B = black, O = other non-white | |||||||||
| *American Joint Committee on Cancer Cancer Staging Manual, 7th Ed. | |||||||||
| †ER & PR: negative = <1%+, positive = ≥1%+, blank = not tested | |||||||||
| ††Her2: negative = not amplified, positive = amplified, blank = not tested | |||||||||